NeuroDerm Announces Start of U.S. Patient Enrollment in Trial 006, a Phase II Trial of ND0612H for Advanced Parkinson’s Disease
June 30, 2016 16:03 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 30, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today...
NeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics to DUODOPA® in Head-To-Head Pilot PK Comparison Trial
June 28, 2016 07:00 ET
|
NeuroDerm Ltd.
- Company to Proceed with Regulatory Development of ND0612H Based on PK Similarity for the Treatment of Parkinson’s Disease in EU – - Company to Host Conference Call and Webcast Today...
NeuroDerm Added to Russell Global Index
June 24, 2016 18:34 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 24, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Presents Three Posters at the 20th International Congress of Parkinson’s Disease and Movement Disorders
June 23, 2016 09:14 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, June 23, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today presented...
NeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data at the 20th International Congress of Parkinson’s Disease and Movement Disorders
June 16, 2016 07:00 ET
|
NeuroDerm Ltd.
- Clinical Trial Evaluating Efficacy, Safety, Tolerability and Pharmacokinetics of Two Dosing Regimens of ND0612 Compared With Oral Standard of Care Treatment in Patients With Advanced Parkinson’s...
NeuroDerm CEO to Present at Jefferies 2016 Healthcare Conference on June 7
May 31, 2016 14:10 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 31, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces First Quarter 2016 Financial Results
May 26, 2016 07:32 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 26, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm to Host First Quarter 2016 Financial Results Conference Call on May 26, 2016
May 17, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 17, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for Parkinson’s Disease
May 09, 2016 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 09, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced...
NeuroDerm Announces 2016 Annual General Meeting of Shareholders
May 05, 2016 10:13 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...